Literature DB >> 3871261

Cyclosporine-induced fetotoxicity in the rat.

R J Mason, A W Thomson, P H Whiting, E S Gray, P A Brown, G R Catto, J G Simpson.   

Abstract

Female Lewis rats mated with DA male rats were given 25 or 10 mg/kg/day cyclosporine (CsA) from the time of mating to 20 days postcoitus when autopsies were performed. At the higher dose, characteristic drug-induced pathological changes in the mother were accompanied by a striking fetotoxic effect, resulting in a high incidence of fetal mortality or in runting. In addition, fetal kidneys that could be examined showed evidence of CsA-induced proximal tubular cell damage. These abnormalities were not found at the lower dosage of CsA. The fetotoxicity observed at 25 mg/kg did not appear to be dependent on major histocompatibility differences between parental strains, since it was also observed, at the same dosage, in syngeneically mated female Lewis rats.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871261

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Pregnancy after renal transplantation: severe intrauterine growth retardation during treatment with cyclosporin A.

Authors:  M D Pickrell; R Sawers; J Michael
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19

Review 2.  Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.

Authors:  W Connell; A Miller
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 3.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

4.  Immunological responses in an infant after cyclosporine A exposure during pregnancy.

Authors:  R Baarsma; W A Kamps
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

5.  Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant.

Authors:  Irena Nulman; Michael Sgro; Maru Barrera; David Chitayat; John Cairney; Gideon Koren
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 6.  Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes.

Authors:  V T Armenti; M J Moritz; J M Davison
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

7.  Cyclosporine therapy during pregnancy in a patient with β-thalassemia major and autoimmune haemolytic anemia: a case report and review of the literature.

Authors:  A Agapidou; E Vlachaki; T Theodoridis; M Economou; V Perifanis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

Review 8.  Immunosuppression in pregnancy: choices for infant and maternal health.

Authors:  Vincent T Armenti; Michael J Moritz; Elyce H Cardonick; John M Davison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Optimisation of antirheumatic drug treatment in pregnancy.

Authors:  M Ostesen
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

10.  Differential effects of the immunosuppressive calcineurin inhibitors cyclosporine-A and tacrolimus on ovulation in a murine model.

Authors:  F Zakerkish; M J Soriano; E Novella-Mestre; M Brännström; C Díaz-García
Journal:  Hum Reprod Open       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.